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Objective: to investigate the associations of oral microbiota, leucocytes count, neutrophil count,
platelet counts and hemoglobin level, and the severity of oral mucositis in pediatric patients with
acute lymphoblastic leukemia (ALL) receiving chemotherapy. Materials and Methods: 71 prospec-
tive patients were included. Analyses of oral microbiota and blood sample were conducted on
days 14 (D14) and 56 (D56) of the Brazilian GBTLI-99 treatment protocol. Herpes simplex virus
(HSV) identification was performed by PCR followed by DNA sequencing analysis. Bacteria and
fungi identification was obtained by standard microbiological culture tests. Results: 103 episodes
of mucositis occurred, being 65 at D14 and 38 at D56. Most cases positive for herpes viral DNA
sequences were identified as HSV-1. At D14, we found a significant association between the sever-
ity of mucositis and presence of HSV-1 (p = 0.0347), Candida spp. (p = 0.0078), and low platelet
count (p = 0.0064). At D56, we found a significant association between the severity of mucositis
and the presence of HSV-1 (p = 0.0317), previous HSV-1 presence on D14 (p < 0.0001) and neu-
trophil count (p = 0.0211). Clinical relevance: the identification of risk factors for mucositis in chil-
dren and adolescents may contribute to the development of new strategies for prevention and/or
treatment, reducing the complications associated with this condition. Conclusions: the presence
of HSV, platelet count, and Candida spp. presence at D14 of ALL induction treatment is associated
with increased severity of mucositis in children and adolescents. At D56 of ALL treatment, mucosi-
tis severity was associated with neutrophil count, HSV presence, and previous presence of HSV (at
D14).
Keywords acute lymphoblastic leukemia, candida spp, hematological parameters, herpes virus,
oral bacteria, oral mucositis
INTRODUCTION
One of the often overlooked and under researched complications of cancer treatment
is oral mucositis (OM), which is defined as inflammation of oral mucosa resulting from
cancer therapy typically manifesting as atrophy, swelling, erythema, and ulceration
[1].
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
Oral Mucositis 
Mouth pain and difficulties in swallowing, eating, drinking, and talking are the
most prevalent and debilitating symptoms, have been shown to affect many patients
throughout the course of OM, and can cause profound psychological distress and
impairment of patients’ quality of life and functional status [2, 3]. Hospitalization
also poses economic constrains on the health care system in addition to its clinical
implications [4].
Oral mucositis begins 3 to 10 days after chemotherapy is initiated and can persist
for 3 weeks. It has been shown to peak at around 7 to 14 days, at which time it slowly
resolves unless complicated by infection [5, 6]. This condition can range from mild to
severe and represents a common cause of dose reduction and treatment delays. Devel-
opment of OM can also increase mortality by nearly 40% in severe cases [7]. Up to 80%
of children undergoing chemotherapy will experience some degree of mucositis, al-
though the incidence of OM differs according to the type of cancer and treatment reg-
imen. Children with hematologic malignancies experience mucositis more frequently
than those with solid tumors. Furthermore, this group of patients is also more likely to
have severe mucositis compared with patients suffering other malignancies [8, 9].
Significant progress has been made in understanding the pathobiology of mucosi-
tis. What was once thought to be a simple reflection of direct epithelial damage in-
duced by cytotoxic therapy is now considered to be a complex phenomenon that also
affects the connective tissue. The model includes events that have been described in
five overlapping stages: initiation, upregulation, message generation, ulceration, and
healing. Initiation involves the generation of reactive oxygen species, direct damage
to cells, tissues and blood vessels, and the start of other biological events that create a
cascade of reactions contributing to tissue damage. Activation of transcription factors
such as nuclear factor-kappa B leads to a local increase in proinflammatory cytokines
including interleukin IL-6, and tumor necrosis factor (TNF). Positive feedback mecha-
nisms result in amplification and acceleration of the process, which finally leads to ul-
ceration. Oral bacteria colonize denuded connective tissues and their cell wall compo-
nents activate macrophages to produce additional inflammatory cytokines. All these
events lead to pain and in neutropenic patients, bacteria may invade into the systemic
circulation causing bacteraemia and sepsis. Following cessation of the injurious ther-
apy, healing occurs and the epithelium appears normal again. However, ongoing al-
terations may occur predisposing for future complications [4, 7].
At present, there is a scarcity in the literature investigating OM in children and the
exact risk factors of the disease in this population are still poorly understood, despite
their increased risk of developing this complication when compared to the adult pop-
ulation [9, 10].
Development of mucositis depends on a number of factors, related to both therapy
and patient characteristics. Treatment variables that may affect the prevalence and
the severity of mucositis include the type, dose, and schedule of systemic cytotoxic
medications, radiation dose and field, and concomitant use of chemotherapy and ra-
diation. Among patient associated factors, age, body mass index, gender, alterations
in salivary production, poor oral health and mucosal trauma have been reported to
influence mucositis [11]. It has become increasingly clear that genetic factors play a
role in toxicity risk [12]. Genetic determinants of mucositis risk include genes that
regulate the availability of active chemotherapy drug metabolites. Oral microflora is
considered to play a secondary role in the pathogenesis of mucositis. Bacteria coloniz-
ing ulcerations may contribute to increased severity and delayed healing. The duration
of mucositis in myeloablative hematopoietic progenitor cell transplantation (HPCT)
was reported to be associated with neutrophil engraftment [13], but the relative con-
tribution of innate and adaptive immunity in mucositis remains to be defined.
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Clinical improvement of mucositis seems to correlate with neutrophil recovery [1,
11]. For patients who have been made neutropenic by their chemotherapy, coincident
mucositis offers a ready portal of entry for oral bacteria. It is not surprising, therefore,
that the presence of mucositis in granulocytopenic cancer patients is strongly associ-
ated with bacteremia and sepsis [7].
Patients with impaired local or systemic immunity, in particular low baseline neu-
trophil levels, are at high risk of infection and mucositis [14]. Furthermore, the devel-
opment of neutropenia during chemotherapy or radiotherapy greatly increases the in-
cidence of oral mucositis. In addition, the time-scale of mucosal healing depends, at
least in part, on that of the recovery of immune function [15, 16].
The objective of this study was to prospectively investigate the associations of
oral microbiota, leucocytes count, neutrophil count, platelet counts and hemoglobin
level, and the severity of oral mucositis in pediatric patients with acute lymphoblastic
leukemia (ALL) receiving chemotherapy.
MATERIALS AND METHODS
Methodology is similar to our recently published study [17]. The study cohort includes
a total of 71 consecutive pediatric ALL patients, enrolled on the Brazilian Childhood
Cooperative Group-protocol ALL-99 (GBTLI ALL-99) [18] and treated at the Boldrini
Children’s Center, from August 2005 to October 2006. All patients received the same
drugs on similar schedules and dosages. Patients were aged 3 to 276 months (mean,
93.8 ± 65.1); 61.1% were male. Parents, legal guardians, or patients, as appropriate,
agreed to participate in the study. Research was conducted with the approval of the
Brazilian National Ethical Committee. The collection of mucosal material and blood
samples was carried out on days 14 and 56 after the beginning of treatment. All pa-
tients treated according to the GBTLI ALL-99 protocol, regardless of risk group, re-
ceived a 4 weeks induction regimen including prednisone, vincristine, doxorubicin,
l-asparaginase, and triple intrathecal therapy (TIT): methotrexate, ara-C and dexam-
ethasone. TIT was performed at D0, D14, D28, and, in addition, at days 7 and 21 if the
patient was positive for central nervous system leukemia.
The severity of mucositis was evaluated according to the criteria established by the
NCI (2003) [19]. The highest mucositis severity reached along the 10-day period of ob-
servation was used for the statistical analysis. All patients received the same orien-
tation regarding oral hygiene and mouth rinsing with physiological saline at 1%. All
patients received routine dental management for oral hygiene, cavity repair, and nec-
essary restorations or extractions. Patients did not receive any prophylactic medicine
for fungus or virus.
On D14, 71 patients were evaluated. On D56, only 67 of the 71 patients were eval-
uated. Although oral samples were collected on D14 and D56, the assessment of oral
mucosa was carried out on a daily basis for up to 10 days. All patients were examined
daily by the same investigator (RMHM).
The presence of different herpes viral species (HSV-1 to HSV−8) was investigated
using the consensus primer polymerase chain reaction (PCR) technique developed
by VanDevanter et al. [20]. The evaluation of fungi and bacteria was determined by
methods of microbiological culture (Sabouraud, Chocolate, Sanguis, and MacConkey
agar). The tests used to identify fungi and bacteria were performed according to the
norms of the American Society of Microbiology [21].
The Fisher t-test was used to analyze the associations between the grade of oral mu-
cositis and the presence of HSV, number of bacteria/mm3, presence of Candida spp.,
leucocytes count, neutrophil count, platelet counts, and hemoglobin level, using a 5%
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significance level. The median value was used as a cutoff point in analyzing data of
bacteria colony numbers. The SAS software was used throughout [22].
RESULTS
We evaluated 44 males (61.9%) and 27 females (38.1%). The mean age ± SD was
93,1 ± 63,4 months (range, 3–228 months) at the time of diagnosis. One hundred and
three episodes of mucositis occurred, being 65 at D14 and 38 at D56. Typically, pa-
tients developed mucosal ulcers, roof of the mouth, lips, and hard palate. The lesions
were followed by pain, hyperemia, and fibrin deposition. The mean time to onset of
oral mucositis was 6.8 ± 3.9 days. Mucositis started to ameliorate at an average time of
9 days, with neutrophils recovered and. Most cases positive for herpes viral DNA se-
quences were identified as having HSV-1. One patient was positive for HSV-4 (EBV) at
D14. More than 95% of patients were positive for Streptococcus viridans and Neisseria
sp on both time points (days 14 and 56).
At D14, we found a significant association between the severity of mucositis and
the presence of HSV-1 (p = 0.0347), Candida spp. (p = 0.0078) and low platelet count
(p = 0.0064 (Table 1).
At D56, we found a significant association between the severity of mucositis and
the presence of HSV-1 (p = 0.0317), previous HSV-1 presence on D14 (p < 0.0001),
and neutrophil count (p = 0.0211) (Table 2).
DISCUSSION
Most researches on the risk factors for OM have been focused on adult patients. Pe-
diatric and adolescent patients are greatly under represented. Further, the majority of
the studies on pediatric and adolescent populations were cross sectional, retrospec-
tive studies or secondary analysis of clinical trials [23]. In this study, the association of
mucositis severity and oral microflora and hematological parameters, in a cohort of
consecutive ALL pediatric patients were prospectively evaluated.
Our findings are consistent with previous studies in which the incidence of OM in
pediatric and adolescent patients receiving chemotherapy was moderately high [24]. A
recent retrospective medical record found a 46% incidence of OM in ALL pediatric pa-
tients undergoing chemotherapy. Patient age (p = 0.33) and gender (p = 0.08) showed
no correlation with the oral mucositis occurrence [25]. Cheng et al. [6, 26], Fadda et al.
[27] and Otmani et al. [9] also reported that no association was found between OM
grades and age or gender in pediatric patients. These results are in agreement with
our data. However, Vokurka et al. [28] suggested that females appear to be more sus-
ceptible to mucositis and that gender may play an important role as an independent
risk factor and as a predictor for OM in high-dose chemotherapy settings.
Chemotherapeutic agents inhibit other rapidly dividing cells, especially those in the
bone marrow. Thus maximum stomatotoxicity is most frequently observed in the nadir
of white blood cell count since oral mucosal cells and leukocytes have essentially the
same renewal rate. In the present study we found a significant association between
mucositis and neutrophil count at D14 of induction of therapy. McCarthy et al. [29]
conducted a prospective cohort study in adult patients to investigate factors associated
with mucositis in adult patients receiving 5-FU for cancer of the digestive tract. Multi-
ple logistic regression analysis indicated that xerostomia at baseline or baseline neu-
trophil level less than 4000 cells/mm3 were significant predictors of mucositis. Their
results are similar to ours; however the study was conducted in adult patients, mak-
ing it difficult to compare results. Cheng et al.[26] conducted a study to determine the
risk factors associated with chemotherapy-induced OM in children and evaluated age,
Copyright C© Informa Healthcare USA, Inc.
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TABLE 1 Mucositis Severity, HSV Presence, Candida spp. Presence, Total Bacteria Count,
Leucocytes Count, Neutrophil Count, Platelet Count, and Hemoglobin Level in Pediatric Patients
with ALL at day 14 of Induction Therapy
Mucositis
Clinical and laboratory data Grade 0 Grade I Grade II Grade III p-value
Age (years)
≤ 5 3 (4.22) 23 (22.29) 3 (4.22) 3(4.22)
> 5 ≤ 10 2 (2.82) 12 (16.90) 2 (2.82) 3 (4.23)
> 10 ≤ 14 0 (0.00) 9 (12.68) 1(1.41) 1(1.41)
≥ 14 1 (1.41) 3 (4.23) 4 (5.63) 1 (1.41)
p = 0.3624
Gender
Female 3 (4.23) 19 (26.76) 2 (2.82) 3 (4.23)
Male 3 (4.23) 28 (39.44) 8 (11.27) 5 (7.04)
p = 0.6161
HSV presence
Negative 6 (8.57) 44 (62.86) 9 (12.86) 1 (1.43)
Positive 0 (0.00) 2 (2.86) 1 (1.43) 7 (10.00)
p < 0.0001
Candida spp. Presence
No 5 (7.04) 39 (54.93) 7 (9.86) 2 (2.82)
Yes 1 (1.41) 8 (11.27) 3 (4.23) 6 (8.45)
p = 0.0078
Leucocytes count (/mm3)
≥3000 0 (0.00) 8 (11.27) 0 (0.00) 0 (0.00)
2000 ≥ <3000 2 (2.82) 12 (16.90) 3 (4.23) 1 (1.41)
1000 ≥ <2000 2 (2.82) 20 (28.17) 3 (4.23) 5 (7.04)
<1000 2 (2.82) 7 (9.86) 4 (5.63) 2 (2.82)
p = 0.5224
Neutrophil count (/mm3)
≥ 1500 0 (0.00) 3 (4.23) 0 (0.00) 0 (0.00)
1000 ≥ < 1500 2 (2.82) 3 (4.23) 0 (0.00) 0 (0.00)
500 ≥ <1000 1 (1.41) 13 (18.31) 0 (0.00) 1 (1.41)
< 500 3 (4.23) 28 (39.44) 10 (14.08) 7 (9.86)
p = 0.1801
Platelet count (/mm3)
≥ 75.000 2 (2.82) 35 (49.30) 4 (5.63) 2 (2.82)
50.000 ≥ <75.000 1 (1.41) 4 (5.63) 0 (0.00) 3 (4.23)
25.000 ≥ <50.000 2 (2.82) 5 (7.04) 3 (4.23) 1 (1.41)
< 25.000 1 (1.41) 3 (4.23) 3 (4.23) 2 (2.82) p = 0.0064
Hemoglobin level (g/dL)
≥ 10.0 0 (0.00) 9 (12.68) 1 (1.41) 1 (1.41)
8.0 ≥ <10.0 3 (4.23) 17 (23.94) 3 (4.23) 3 (4.23)
6.5 ≥ <8.0 2 (2.82) 11 (15.49) 2 (2.82) 1 (1.41)
< 6.5 1 (1.41) 10 (14.08) 4 (5.63) 3 (4.23) p = 0.9366
Total CFUb of bacteria/mm3
≤380.000 3 (4.23) 26 (36.62) 4 (5.63) 4 (5.63)
> 380.000 3 (4.23) 21 (29.58) 6 (8.45) 4 (5.63) p = 0.892
aBecause of poor DNA quality, 1 patients’ sample was excluded from PCR analysis at D14.
bCFU = colony-forming units
type of cancer and chemotherapy regimen. These authors suggest that neutropenia
may be one important risk factor. Their finding is consistent with current understand-
ing of indirect cytotoxicity in the pathogenesis of OM [4]. It has been suggested that a
decrease in the neutrophil count may result in an impaired ability to promote an ad-
equate inflammatory response to the chemotherapy cytotoxic effects on the oral mu-
cosa. In addition, in the absence of adequate neutrophil counts or function, relatively
minor mucosal toxicity may progress to overt ulceration, because of an impaired basic
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TABLE 2 Mucositis Severity, HSV Presence, Candida spp. Presence, Total Bacteria Count,
Leucocytes Count, Neutrophil Count, Platelet Count, and Hemoglobin Level in Pediatric Patients
with ALL at day 56 of Induction Therapy
Mucositis
Clinical and laboratory data Grade 0 Grade I Grade II Grade III p-value
Age (years)
≤ 5 15 (22.39) 10 (14.93) 1 (1.49) 4 (5.97)
> 5 ≤ 10 6 (8.96) 8 (11.94) 5 (7.46) 0 (0.00)
> 10 ≤ 14 5 (7.46) 3 (4.48) 1 (1.49) 2 (2.99)
≥ 14 3 (4.48) 4 (5.97) 0 (0.00) 0 (0.00)
p = 0.2057
Gender
Female 11 (16.42) 6 (8.96) 5 (7.46) 3 (4.48)
Male 18 (26.87) 19 (28.36) 2 (2.99) 3 (4.48)
p = 0.1238
HSV presence at D56a
Negative 28 (43.08) 24 (36.92) 6 (89.23) 3 (4.62)
Positive 0 (0.00) 0 (0.00) 1 (1.54) 3 (4.62)
p < 0.0001
Previous HSV presence at D14a
Negative 27 (41.54) 23 (35.38) 7 (10.77) 1 (1.54)
Positive 2 (3.08) 1 (1.54) 0 (0.00) 4 (6.15)
p < 0.0001
Previous mucositis at D14
No 1 (1.49) 2 (2.99) 1 (1.49) 0 (0.00)
Yes 28 (41.79) 23 (34.33) 6 (8.96) 6 (8.96)
p = 0.5422
Leucocytes count (/mm3)
≥3000 12 (17.91) 9 (13.43) 2 (2.99) 2 (2.99)
2000 ≥ <3000 13 (19.40) 12 (17.91) 1 (1.49) 2 (2.99)
1000 ≥ <2000 3 (4.48) 3 (4.48) 2 (2.99) 2 (2.99)
<1000 1 (1.49) 1 (1.49) 2 (2.99) 0 (0.00)
p = 0.3366
Neutrophil count (/mm3)
≥ 1500 14 (20.90) 8 (11.94) 2 (2.99) 2 (2.99)
1000 ≥ < 1500 10 (14.93) 9 (13.43) 0 (0.00) 3 (4.48)
500 ≥ <1000 4 (5.97) 4 (5.97) 0 (0.00) 1 (1.49)
< 500 1 (1.49) 4 (5.97) 5 (7.46) 0 (0.00)
p = 0.0211
Platelet count (/mm3)
≥ 75.000 26 (38.81) 22 (32.84) 6 (8.96) 6 (8.96)
50.000 ≥ <75.000 2 (2.99) 0 (0.00) 1 (1.49) 0 (0.00)
25.000 ≥ <50.000 0 (0.00) 3 (4.48) 0 (0.00) 0 (0.00)
< 25.000 1 (1.49) 0 (0.00) 0 (0.00) 0 (0.00)
p = 1.000
Hemoglobin level (g/dL)
≥ 10.0 10 (14.93) 11 (16.42) 0 (0.00) 3 (4.48)
8.0 ≥ <10.0 9 (13.43) 8 (11.94) 2 (2.99) 3 (4.48)
6.5 ≥ <8.0 9 (13.43) 3 (4.48) 3 (4.48) 0 (0.00)
< 6.5 1 (1.49) 3 (4.48) 2 (2.99) 0 (0.00)
p = 0.1097
Total CFUb of bacteria/mm3
≤ 300.000 13 (19.40) 16 16 (23.88) 3 (4.48) 5 (7.46)
> 300.000 (23.88) 9 (13.43) 4 (5.97) 1 (1.49)
p = 0.2314
Candida spp. presence
No 24 (35.82) 22 (32.84) 6 (8.96) 5 (7.46)
Yes 5 (7.46) 3 (4.48) 1 (1.49) 1 (1.49)
p = 0.9491
aBecause of poor DNA quality, 2 patients’ samples were excluded from PCR analysis at D56.
bCFU = colony-forming units
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repair response [30]. An inverse relationship between neutrophil counts and the sever-
ity of OM has been reported by several investigators [6, 31, 32]. In the present study
was observed an inverse association between platelets count and mucositis grade (p =
0.0064). These results are in agreement with the results of previous study [32]. Probably
the bleeding related to lower platelet counts difficult the ulcers healing and increase
the severity of mucositis.
We found no association between hemoglobin levels and mucositis intensity in the
studied patients. Ye et al. [32] showed that before chemotherapy a more heteroge-
neous bacterial community was found in the patients who later developed OM com-
pared with no mucositis group. In addition, they found a more pronounced shift of
the bacterial composition after the initiation of chemotherapy in patients who later
developed OM compared with those who did not, indicating that oral microbial ‘sta-
bility’ might be beneficial. We do not found a direct association between the count
of CFU bacteria of the oral cavity and mucositis severity (p = 0.8921 and p = 0.2314,
at D14 and D56 respectively). As described in a previous publication, one possible
explanation for the lack of this relationship is that patients under chemo treatment
used trimethoprim–sulfamethoxazole prophylactically, which caused a reduction in
the oral bacterial microbiota, or the dental preventive treatment received by patients,
which may have led to a significant decrease in the bacterial population [17]. Anirud-
han et al. [33] studied 70 children and found no significant difference in oral bacteria
prevalence between groups of patients with mild and severe mucositis.
In this study, it was shown that the presence of Candida spp. is associated with in-
creased severity of mucositis but these results are in conflict with Anirudhan et al. [8]
who found no significant difference in fungi prevalence between groups of patients
with mild and severe mucositis.
According to Sonis [34] speculation that HSV-1 might be associated with the de-
velopment of mucositis has been mentioned in the literature since at least the 1980s.
However, Aggarwal et al.[35] has confirmed a high (66%) prevalence of HSV-1 in oral
mucositis in children receiving chemotherapy for cancer, but found no association
of HSV-1 with mucositis severity. These authors believe that a relatively small sample
size with a reasonably high prevalence of HSV could be the confounding factors for
identifying such association. Herpes simplex (mainly HSV-1) stands out among the
viral agents related to infections in pediatric leukemia patients, in whom the virus
is found most frequently in lesions located in the oral mucosa [36]. Figliolia et al.
[25] retrospectively analyzed records from 169 children with ALL and herpes was
recorded in 13 (16.9%) patients. Santos de Faria et al.[37] analyzed the data of 92
patients diagnosed with ALL and considered the HSV-1 virus as a risk factor for the
mucositis severity. These findings are in agreement with the results of the present
research, which demonstrated that infection by HSV was a risk factor for aggravation
of the severity of mucositis.
CONCLUSION
We conclude that the presence of HSV, platelet count, and Candida spp. presence at
D14 of ALL induction treatment is associated with increased severity of mucositis in
children and adolescents with this disease. At D56 of ALL treatment, mucositis severity
was associated with neutrophil count, HSV presence, and previous presence of HSV
(at D14).
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[18] Scrideli CA, Assumpção JG, Ganazza MA, Araújo M, Toledo SR, Lee ML, Delbuono E, Petrilli AS,
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